Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study (Q46276281)

From Wikidata

Jump to navigation Jump to search

scientific article published in October 2008

Language	Label	Description	Also known as
English	Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study	scientific article published in October 2008

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

multiple sclerosis

0 references

0 references

relapsing-remitting multiple sclerosis

0 references

1 reference

based on heuristic

inferred from title

1

object named as

Ludwig Kappos

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

2

object named as

Ralf Gold

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

David H. Miller

3

object named as

David H Miller

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

author name string

David G Macmanus

4

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Eva Havrdova

5

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Volker Limmroth

6

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Chris H Polman

7

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Klaus Schmierer

8

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Tarek A Yousry

9

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Minhua Yang

10

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Mefkûre Eraksoy

11

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Eva Meluzinova

12

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Ivan Rektor

13

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Katherine T Dawson

14

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Alfred W Sandrock

15

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Gilmore N O'Neill

16

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

BG-12 Phase IIb Study Investigators

17

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

language of work or name

0 references

publication date

1 October 2008

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

372

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

9648

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

1463-1472

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

An Nrf2/Small Maf Heterodimer Mediates the Induction of Phase II Detoxifying Enzyme Genes through Antioxidant Response Elements

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Stabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic [correction of electrophillic] phase II inducers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Fibroblast growth factor-1 induces heme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal cord astrocytes: consequences for motor neuron survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Promoting remyelination in multiple sclerosis by endogenous adult neural stem/precursor cells: defining cellular targets.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Vacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor Nrf2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Detoxication enzyme inducers modify cytokine production in rat mixed glial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Reactive oxygen species are required for the phagocytosis of myelin by macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of reactive oxygen species in the pathogenesis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement of low-molecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(08)61619-0

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46276281&oldid=2116008429"